NCT02279329 Longitudinal Study of Helium-3 and Xenon-129 Magnetic Resonance Imaging
| NCT ID | NCT02279329 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Grace Parraga |
| Condition | COPD |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2009-05 |
| Primary Completion | 2025-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2009-05 with a primary completion date of 2025-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Subjects male and female aged 50-85 with a clinical diagnosis of chronic obstructive pulmonary disease (COPD) or Bronchiectasis, or those with ≥ 10 pack/years smoking history will be imaged with CT and MRI for the development of tools to quantify and validate longitudinal in vivo magnetic resonance imaging phenotypes of COPD and Bronchiectasis.
Eligibility Criteria
Inclusion Criteria: * Subjects male and female aged 50-85 with either A) a clinical diagnosis of COPD or Bronchiectais or B) \>10 pack/year smoking history * Subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent * Subject must be able to perform a breathhold for 16s. * Subject is judged to be in otherwise stable health on the basis of medical history * Subject is ambulatory and can perform the 6MWT * Subject able to perform reproducible pulmonary function testing (i.e., the 3 best acceptable spirograms have FEV1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater.) * FEV1 \>25% predicted * FVC \> 25% predicted and \>0.5L Exclusion Criteria: * Patient is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material. * Subject has a daytime room air oxygen saturation \<90% while lying supine. * Patient is unable to perform spirometry or plethysmography maneuvers * Patient is pregnant * In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia. * Subject has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants.)
Contact & Investigator
Grace E Parraga, PhD
PRINCIPAL INVESTIGATOR
Robarts Research Institute, The University of Western Ontario
Frequently Asked Questions
Who can join the NCT02279329 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02279329 currently recruiting?
Yes, NCT02279329 is actively recruiting participants. Contact the research team at gparraga@robarts.ca for enrollment information.
Where is the NCT02279329 trial being conducted?
This trial is being conducted at London, Canada.
Who is sponsoring the NCT02279329 clinical trial?
NCT02279329 is sponsored by Dr. Grace Parraga. The principal investigator is Grace E Parraga, PhD at Robarts Research Institute, The University of Western Ontario. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.